Pro Medicus (ASX:PME) share price dips despite positive update

What’s happening to the company’s share price?
The post Pro Medicus (ASX:PME) share price dips despite positive update appeared first on The Motley Fool Australia. –

The Pro Medicus Limited (ASX: PME) share price is falling by the wayside today regardless of the company announcing a positive update.

At the time of writing, Pro Medicus shares are down 1.25% to $53.93. This means that its shares have now dropped 10.5% in a month.

What’s dragging Pro Medicus shares lower?

A catalyst for the Pro Medicus share price falling into the red today is the broader market weakness.

The S&P/ASX 200 Index (ASX: XJO) is tumbling 1.72% lower to 7,205 points following the Dow Jones’ heavy losses overnight.

In today’s statement, Pro Medicus advised its wholly-owned United States (US) subsidiary, Visage Imaging, Inc has signed its equal-largest contract to date.

The 7-year, $40 million deal is with US leading healthcare provider, Novant Health.

Headquartered in North Carolina, Novant Health is a community-based integrated delivery network (IDN) that spans three states.

The company services 6 million patients annually across 15 medical centres and hundreds of outpatient facilities and physician clinics.

Based on a transactional licensing model, the contract will see Pro Medicus’ Visage products implemented throughout Novant Health. This includes its Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module.

The suite will be employed in the Microsoft Azure cloud, delivering a unified diagnostic imaging platform across the network.

Planning for the rollout is to commence immediately, with initial go-lives targeted for the second half of the financial year.

The latest deal represents Pro Medicus’ seventh major North American contract in less than 18 months.

The health imaging software company has doubled down on its efforts to rapidly grow in the North American market.

Novant Health joins an increasing number of Visage clients that opt for a fully cloud-based solution. This is a rising trend amongst healthcare providers across the US.

Management commentary

Pro Medicus CEO, Dr Sam Hupert said:

… Like several of our other recent deals, it includes more than one of our products, in this case, Visage 7 Workflow as well as Visage 7 Viewer, validating our strategy of providing clients maximum flexibility by offering a highly modular, multi-product solution.

Our pipeline remains strong. Deals like this confirm our view that Visage 7, with its proven cloud-native technology and modular design, provides us with a significant strategic advantage that enables us to address opportunities across a growing segment of the market both in North America and other regions.

About the Pro Medicus share price

Over the past 12 months, Pro Medicus shares have accelerated to post a 102% gain, with year-to-date up 53%.

The company is trading on a price-to-earnings (P/E) ratio of 185.15 and commands a market capitalisation of roughly $5.7 billion.

The post Pro Medicus (ASX:PME) share price dips despite positive update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Pro Medicus right now?

Before you consider Pro Medicus, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

5 things to watch on the ASX 200 on Friday

The Pro Medicus (ASX:PME) share price is surging 5% on Thursday
Why Afterpay, Mineral Resources, Pilbara Minerals, & Pro Medicus shares are falling

The healthcare sector is weighing on the ASX 200 on Tuesday

2 small-cap ASX shares with an edge over rivals

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!